Enzalutamide + Androgen deprivation therapy (ADT)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Castration Resistant Prostate Cancer
Conditions
Metastatic Castration Resistant Prostate Cancer
Trial Timeline
Sep 19, 2018 → Feb 20, 2024
NCT ID
NCT03641560About Enzalutamide + Androgen deprivation therapy (ADT)
Enzalutamide + Androgen deprivation therapy (ADT) is a approved stage product being developed by Astellas Pharma for Metastatic Castration Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03641560. Target conditions include Metastatic Castration Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03641560 | Approved | Completed |
Competing Products
20 competing products in Metastatic Castration Resistant Prostate Cancer